New diabetes clinical trial: A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)
Published on: 2026-06-02T04:00:00Z
Conditions: End Stage Kidney Disease (ESKD)
Interventions: Biological: CSL300; Other: Placebo
Sponsors: CSL Behring
Not yet recruiting
https://ift.tt/hDBH6We
Conditions: End Stage Kidney Disease (ESKD)
Interventions: Biological: CSL300; Other: Placebo
Sponsors: CSL Behring
Not yet recruiting
https://ift.tt/hDBH6We
Comments
Post a Comment